Castle Biosciences wins NY health department approval for AdvanceAD-Tx test
CSTL•New York clearance for AdvanceAD-Tx
Castle Biosciences received New York State Department of Health assay clearance for its AdvanceAD-Tx test for moderate-to-severe atopic dermatitis.
The non-invasive gene expression test guides systemic therapy selection for patients aged 12 or older, classifying likely response to JAK inhibitors versus Th2-targeted biologics.
The decision expands access in New York, a state that formally reviews laboratory-developed tests before patient use.
